Drugs / CP-506
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04954599 | May 2023 → Feb 2027 expected | cancer of unknown primary site | Maastricht University Medical Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CP-506 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04954599 ↗ |
| Modality | Other / unclassified | “hypoxia-activated DNA alkylating agent” NCT04954599 ↗ |
| Route | Intravenous | “intravenous infusion of CP-506” NCT04954599 ↗ |